1. Home
  2. ANAB vs PRGS Comparison

ANAB vs PRGS Comparison

Compare ANAB & PRGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AnaptysBio Inc.

ANAB

AnaptysBio Inc.

SELL

Current Price

$47.64

Market Cap

1.4B

Sector

Health Care

ML Signal

SELL

Logo Progress Software Corporation (DE)

PRGS

Progress Software Corporation (DE)

N/A

Current Price

$44.33

Market Cap

1.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
ANAB
PRGS
Founded
2005
1981
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
ANAB
PRGS
Price
$47.64
$44.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
5
Target Price
★ $87.25
$56.20
AVG Volume (30 Days)
447.0K
★ 459.0K
Earning Date
11-17-2026
09-30-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 91.02
7.79
EPS
N/A
★ 1.58
Revenue
$234,603,000.00
★ $397,572,000.00
Revenue This Year
N/A
$7.13
Revenue Next Year
$69.42
$22.19
P/E Ratio
★ N/A
$28.41
Revenue Growth
★ 157.01
N/A
52 Week Low
$30.27
$23.82
52 Week High
$73.30
$47.25

Technical Indicators

Market Signals
Indicator
ANAB
PRGS
Relative Strength Index (RSI) 44.91 56.13
Support Level $44.38 $42.21
Resistance Level $51.94 $43.98
Average True Range (ATR) 2.27 1.61
MACD 0.25 0.16
Stochastic Oscillator 44.55 63.28

Price Performance

Historical Comparison
ANAB
PRGS

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About PRGS Progress Software Corporation (DE)

Progress Software Corp provides software products that enable customers to develop, deploy, and manage AI-powered applications and digital experiences. The Company operates across North America, Latin America, Europe, the Middle East and Africa (EMEA), and Asia Pacific through subsidiaries and distributors, generating a majority of its revenue from the United States. Its product portfolio includes Progress Agentic RAG, Automate MFT, Chef, Corticon, DataDirect, Developer Tools, Flowmon, Kemp LoadMaster, MarkLogic, MOVEit, OpenEdge, Semaphore, ShareFile, Sitefinity, and WhatsUp Gold, offering solutions for application development, data connectivity, DevOps automation, managed file transfer, network security, and digital experience. It generates maximum revenue from the United States.

Share on Social Networks: